Page last updated: 2024-12-05

metyrapone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Metyrapone is a medication used to test the function of the adrenal glands. It is a potent inhibitor of 11β-hydroxylase, an enzyme involved in the synthesis of cortisol. Metyrapone blocks the production of cortisol by the adrenal glands, which leads to an increase in the production of ACTH (adrenocorticotropic hormone) by the pituitary gland. The increased ACTH levels can then be measured in the blood or urine. This test is used to diagnose conditions such as Cushing's syndrome, adrenal insufficiency, and pituitary tumors. Metyrapone is also used to treat Cushing's syndrome in some cases. It is usually taken orally. Metyrapone can cause side effects, including nausea, vomiting, headache, and dizziness. It can also interact with other medications, so it is important to tell your doctor about all the medications you are taking. The synthesis of metyrapone involves a multi-step process, starting with the reaction of 2-methylpyridine with benzoyl chloride, followed by a series of reactions to introduce the required functional groups. The importance of metyrapone lies in its ability to provide valuable diagnostic information about adrenal function, aiding in the diagnosis and management of various endocrine disorders.'

Metyrapone: An inhibitor of the enzyme STEROID 11-BETA-MONOOXYGENASE. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of CUSHING SYNDROME. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

metyrapone : An aromatic ketone that is 3,3-dimethylbutan-2-one in which the methyl groups at positions 1 and 4 are replaced by pyridin-3-yl groups. A steroid 11beta-monooxygenase (EC 1.14.15.4) inhibitor, it is used in the diagnosis of adrenal insufficiency. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID4174
CHEMBL ID934
CHEBI ID44241
SCHEMBL ID637432
MeSH IDM0013712

Synonyms (134)

Synonym
MLS001066377
smr000059134
BIDD:PXR0082
BRD-K46862739-001-03-6
1-propanone, 2-methyl-1,2-di-3-pyridinyl-
metapyron
nsc-25265
methopyrone
methopyrinine
metopyrone
su 4885
1-propanone,2-di-3-pyridinyl-
metapirone
nsc25265
methapyrapone
2-methyl-1,2-di-3-pyridyl-1-propanone
metyrapon
metopiron
1-propanone,2-di-3-pyridyl-
mepyrapone
metopirone
methopirapone
methopyrapone
BPBIO1_000824
PRESTWICK2_000904
einecs 200-206-2
2-methyl-1,2-bis(3-pyridyl)-1-propanone
hsdb 2500
metyraponum [inn-latin]
metirapona [inn-spanish]
methbipyranone
1-propanone, 1,2-di-3-pyridyl-2-methyl-
1-propanone, 2-methyl-1,2-di-3-pyridyl-
nsc 25265
1,2-di-3-pyridyl-2-methyl-1-propanone
2-methyl-1,2-di-3-pyridinyl-1-propanone
NCGC00016242-01
cas-54-36-4
BSPBIO_000748
PRESTWICK3_000904
MLS001335882
MLS001335881
myt ,
EU-0009322
AB00513955
C07205
54-36-4
metyrapone
2-methyl-1,2-di-3-pyridyl-1-propanone, 96%
metyraponum
CHEBI:44241 ,
metirapona
2-methyl-1,2-dipyridin-3-ylpropan-1-one
DB01011
metopirone (tn)
metyrapone (jp17/usp/inn)
D00410
NCGC00161837-01
PRESTWICK1_000904
PRESTWICK0_000904
SPBIO_002947
2-methyl-1,2-dipyridin-3-yl-propan-1-one
HMS2094I07
CHEMBL934 ,
HMS1570F10
bdbm50028166
HMS2097F10
HMS3259O05
2-methyl-1,2-bis(3-pyridyl)propan-1-one
A830124
nsc-760076
nsc760076
pharmakon1600-01506014
dtxsid1023314 ,
dtxcid803314
tox21_110323
AKOS015919707
HMS2235E16
NCGC00016242-02
NCGC00016242-03
metroprione
unii-zs9kd92h6v
metyrapone [usan:usp:inn:ban:jan]
zs9kd92h6v ,
FT-0603230
metyrapone [who-dd]
metyrapone [usan]
metyrapone [inn]
metyrapone [jan]
metyrapone [usp monograph]
metyrapone [orange book]
metyrapone [hsdb]
metyrapone [mart.]
metyrapone [vandf]
metyrapone [mi]
metyrapone [usp-rs]
S5416
HMS3371B16
gtpl5224
CCG-213598
SCHEMBL637432
2-methyl-1,2-bis(pyridin-3-yl)propan-1-one
NC00462
tox21_110323_1
NCGC00016242-05
CS-4879
2-methyl-1,2-di(3-pyridinyl)-1-propanone #
HY-B1232
AB00513955_07
sr-01000765398
SR-01000765398-2
metyrapone, united states pharmacopeia (usp) reference standard
metyrapone, >=98% (hplc), solid
HMS3714F10
su-4885; su 4885; su4885
BCP19099
EX-A1403
Q821641
2-methyl-1,2-di(pyridin-3-yl)propan-1-one
HMS3869K13
AMY832
HMS3742E21
D70339
AS-56195
metyrapone (usan:usp:inn:ban:jan)
v04cd01
metyrapone (usp monograph)
metyrapone (usp-rs)
metyrapone (mart.)
1-propanone, 2-methyl-1,2-di-3-pyridinyl
metyraponum (inn-latin)
metirapona (inn-spanish)
EN300-18532278
Z2289798161

Research Excerpts

Overview

Metyrapone is a glucocorticoid synthesis inhibitor known to induce a stress-like biological syndrome, but also to limit stress-related behaviours. It is a cytochrome P(450) inhibitor that protects against ischemia- and excitotoxicity-induced brain damages in rodents.

ExcerptReferenceRelevance
"Metyrapone (MET) is an inhibitor of 11β-hydroxylase: retrospective studies reported a decrease of cortisol secretion in 50% of cases."( Metyrapone treatment in Cushing's syndrome: a real-life study.
Albiger, N; Antonelli, G; Barbot, M; Boscaro, M; Ceccato, F; Plebani, M; Sabbadin, C; Scaroni, C; Watutantrige-Fernando, S; Zilio, M, 2018
)
2.64
"Metyrapone is a glucocorticoid synthesis inhibitor known to induce a stress-like biological syndrome, but also to limit stress-related behaviours. "( Metyrapone decreases locomotion acutely.
Alonso, A; Brahimi, S; Buguet, A; Canini, F; Cespuglio, R; Drouet, JB; Michel, V, 2009
)
3.24
"Metyrapone is a glucocorticoid synthesis inhibitor largely used to study glucocorticoid involvement in stress and memory processes. "( Single administration of metyrapone modifies sleep-wake patterns in the rat.
Buguet, A; Canini, F; Cespuglio, R; Drouet, JB; Maury, R; Michel, V; Rousset, C, 2011
)
2.12
"Metyrapone is a cytochrome P(450) inhibitor that protects against ischemia- and excitotoxicity-induced brain damages in rodents. "( Metyrapone effects on systemic and cerebral energy metabolism.
Alonso, A; Batandier, C; Buguet, A; Canini, F; Cespuglio, R; Drouet, JB; Fauvelle, F; Fidier, N; Maury, R; Peinnequin, A; Poulet, L, 2012
)
3.26
"Metyrapone, which is a model substrate for studying the reductive properties of oxidoreductases, is itself effectively reduced to the corresponding alcohol by the enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD 1)."( 11beta-Hydroxysteroid dehydrogenase type 1: tissue-specific expression and reductive metabolism of some anti-insect agent azole analogues of metyrapone.
Bannenberg, G; Bélai, I; Martin, HJ; Maser, E, 2003
)
1.24
"Metyrapone is an effective adjunct in the treatment of major depression, accelerating the onset of antidepressant action. "( Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.
Jahn, H; Kellner, M; Kiefer, F; Schick, M; Wiedemann, K; Yassouridis, A, 2004
)
3.21
"Metyrapone is a phenobarbitone-type inducer in rats."( Induction of hepatic cytochrome P-450 and drug metabolism by metyrapone in the rat: relevance to its effects in rat-liver cell culture.
Lake, BG; Paine, AJ, 1983
)
1.23
"The metyrapone test is a useful test in the assessment of outcome of pituitary surgery for Cushing's disease, with a sensitivity of 100% and a specificity of 75% for the early detection of patients at risk of a relapse. "( Postoperative metyrapone test in the early assessment of outcome of pituitary surgery for Cushing's disease.
de Herder, WW; de Jong, FH; Lamberts, SW; van Aken, MO; van der Lely, AJ, 1997
)
1.22
"Thus metyrapone is a 'PB-like' inducer."( Immunochemical quantification of cytochrome P450IA and IIB subfamilies in the livers of metyrapone-treated rats. Relevance to the ability of metyrapone to prevent the loss of cytochrome P-450 in rat hepatocyte culture.
Paine, AJ; Shean, K, 1990
)
0.96

Effects

Metyrapone has been labelled with radioiodine selectively in the 4'-position of ring B. It is the only agent we know of which selectively inhibits 11-oxoreductase.

ExcerptReferenceRelevance
"Metyrapone (MT) has been used clinically to decrease glucocorticoid levels in human and animal studies. "( Evidence that metyrapone in the presence of inflammation modulates cytokine mRNA expression.
Andersen, ML; Benatti, BB; Casati, MZ; Nociti, FH; Peruzzo, DC; Tufik, S, 2010
)
2.16
"Metyrapone has been labelled with radioiodine selectively in the 4'-position of ring B. "( Synthesis of radioiodinated metyrapone--a potential adrenal imaging agent.
Robien, W; Zolle, I, 1983
)
2
"Metyrapone has multiple effects on extra-adrenal corticosteroid metabolism and is the only agent we know of which selectively inhibits 11-oxoreductase. "( Extra-adrenal effects of metyrapone include inhibition of the 11-oxoreductase activity of 11 beta-hydroxysteroid dehydrogenase: a model for 11-HSD I deficiency.
Checkley, SA; Raven, PW; Taylor, NF, 1995
)
2.04

Actions

Metyrapone treatment to lower circulating cortisol levels resulted in a 3.5-fold elevation of ammonia excretion rates. The drug also enhanced mRNA expression of two of the toadfish Rh isoforms (Rhcg1 and Rhcg2)

ExcerptReferenceRelevance
"Metyrapone treatment to lower circulating cortisol levels resulted in a 3.5-fold elevation of ammonia excretion rates, enhanced mRNA expression of two of the toadfish Rh isoforms (Rhcg1 and Rhcg2), and decreased branchial and hepatic GS activity."( Interactions between cortisol and Rhesus glycoprotein expression in ureogenic toadfish, Opsanus beta.
Gilmour, KM; McDonald, MD; Rodela, TM; Walsh, PJ, 2012
)
1.1
"Metyrapone caused an increase in awakenings and a marked decrease in quantitative measures of delta sleep that was significantly greater in controls compared to PTSD."( Delta sleep response to metyrapone in post-traumatic stress disorder.
Lenoci, M; Maglione, ML; Marmar, CR; Metzler, TJ; Neylan, TC; Otte, C; Rosenlicht, NZ; Schoenfeld, FB; Yehuda, R, 2003
)
1.35
"Metyrapone caused an increase in the volume of distribution of cortisol (34%) and in the MCR (75%); the half-life was decreased by 25%."( Extraadrenal effects of metyrapone in man.
Fukushima, DK; Levin, J; Zumoff, B, 1978
)
1.29

Treatment

Metyrapone and melatonin treatment significantly (P≤0.05) reduced the thermal-stress-induced increase in plasma concentrations of cortisol and corticosterone. The metyrapone treated hypoxic animals performed better in the Morris Water Maze.

ExcerptReferenceRelevance
"Metyrapone treatment increased the rats' exploration immediately and ten days after stress."( The resilience of adolescent male rats to acute stress-induced delayed anxiety is age-related and glucocorticoid release-dependent.
Campos-Cardoso, R; Dos Santos, NB; Garcia-Cairasco, N; Godoy, LD; Lazarini-Lopes, W; Munhoz, CD; Novaes, LS; Padovan, CM; Perfetto, JG, 2023
)
1.63
"Metyrapone treatment prevented the elevation of corticosterone plasma levels induced by REM sleep deprivation, whereas corticosterone administration to REM sleep-deprived rats resulted in lower corticosterone levels than in non-sleep deprived rats."( Role of corticosterone on sleep homeostasis induced by REM sleep deprivation in rats.
Machado, RB; Suchecki, D; Tufik, S, 2013
)
1.11
"Metyrapone treatment prevented this effect in stressed animals having no effects in handled rats."( Inhibition of the glucocorticoid synthesis reverses stress-induced decrease in rat's 50-kHz ultrasonic vocalizations.
Kos, T; Nikiforuk, A; Pluta, H; Popik, P; Rojek, K; Ryguła, R, 2014
)
1.12
"Metyrapone-treated males continued to court females at levels similar to those of control-treated snakes, suggesting that appetitive reproductive and ingestive behaviors are not mutually exclusive during this life-history transition."( Sex or candy? Neuroendocrine regulation of the seasonal transition from courtship to feeding behavior in male red-sided garter snakes (Thamnophis sirtalis parietalis).
Lutterschmidt, DI; Maine, AR, 2014
)
1.12
"Metyrapone pretreatment dose-dependently decreased cocaine self-administration as demonstrated previously."( Role of GABA-active neurosteroids in the efficacy of metyrapone against cocaine addiction.
Goeders, NE; Guerin, GF; Schmoutz, CD, 2014
)
1.37
"Metyrapone pretreatment allowed us to prevent the acute corticosterone response to CRF and avoid the lasting effects of glucocorticoid deficiency."( [Metyrapone effect on gastroprotective action of corticotropin-releasing factor administered centrally against indomethacin-induced gastric injury].
Bagaeva, TR; Filaretova, LP; Miazina, MA, 2014
)
2.03
"Metyrapone pretreatment shortly inhibited corticosterone rise, caused by ischemic preconditioning, and prevented the gastroprotective action of ischemic preconditioning."( Ischemic preconditioning attenuates gastric ischemia-reperfusion injury through involvement of glucocorticoids.
Bagaeva, T; Bobryshev, P; Filaretova, L, 2009
)
1.07
"Metyrapone and melatonin treatment significantly (P≤0.05) reduced the thermal-stress-induced increase in plasma concentrations of cortisol and corticosterone while significantly (P≤0.05) increased the plasma melatonin on days 11 and 17."( Pineal-adrenal-immune system relationship under thermal stress: effect on physiological, endocrine, and non-specific immune response in goats.
Sejian, V; Srivastava, RS, 2010
)
1.08
"The metyrapone treated hypoxic animals performed better in the Morris Water Maze."( Corticosterone synthesis inhibitor metyrapone ameliorates chronic hypobaric hypoxia induced memory impairment in rat.
Baitharu, I; Barhwal, K; Deep, SN; Hota, SK; Ilavazhagan, G; Jain, V; Malhotra, AS; Prasad, D, 2012
)
1.14
"Metyrapone treatment to lower circulating cortisol levels resulted in a 3.5-fold elevation of ammonia excretion rates, enhanced mRNA expression of two of the toadfish Rh isoforms (Rhcg1 and Rhcg2), and decreased branchial and hepatic GS activity."( Interactions between cortisol and Rhesus glycoprotein expression in ureogenic toadfish, Opsanus beta.
Gilmour, KM; McDonald, MD; Rodela, TM; Walsh, PJ, 2012
)
1.1
"Metyrapone-treated rats had significantly lower epinephrine and higher norepinephrine production than control rats."( Metyrapone-induced glucocorticoid depletion modulates tyrosine hydroxylase and phenylethanolamine N-methyltransferase gene expression in the rat adrenal gland by a noncholinergic transsynaptic activation.
Bernet, F; Dupouy, JP; Laborie, C; Montel, V; Van Camp, G, 2003
)
2.48
"Metyrapone treatment succeeded in blocking the post-exercise rise in plasma cortisol (17+/-2 vs 118+/-13 ng ml(-1) in controls at time 0), and cortisol injection resulted in a larger and more prolonged cortisol increase than in controls (159+/-22 vs 121+/-14 ng ml(-1) in controls at 1 h)."( A regulatory role for cortisol in muscle glycogen metabolism in rainbow trout Oncorhynchus mykiss Walbaum.
Milligan, CL, 2003
)
1.04
"Metyrapone treatment significantly shortened the length of time it took animals to entrain to the new LD cycle (11.5% acceleration)."( Inhibiting cortisol response accelerates recovery from a photic phase shift.
Cashen, K; Lee, TM; Mohawk, JA, 2005
)
1.05
"Metyrapone treatment did not affect performance during extinction or pre-CS freezing behavior."( Behavioral effects of metyrapone on Pavlovian extinction.
Barrett, D; Gonzalez-Lima, F, 2004
)
1.36
"Metyrapone treatment was well tolerated without serious adverse effects."( Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.
Jahn, H; Kellner, M; Kiefer, F; Schick, M; Wiedemann, K; Yassouridis, A, 2004
)
2.49
"Metyrapone treatment was associated with a significant decrease in plasma cortisol level; the cortisol nadir was 4.84 +/- 1.22 microg/dl during placebo and 2.80 +/- 0.65 microg/dl during metyrapone treatment (P = 0.009). "( Inhibition of cortisol biosynthesis decreases circulating leptin levels in obese humans.
Dagogo-Jack, S; Tykodi, G; Umamaheswaran, I, 2005
)
1.77
"Metyrapone pretreatment did not affect oxytocin-induced/-stimulated lung fluid absorption, while completely blocking IL-1beta-induced/-stimulated fluid absorption."( Oxytocin-induced labor augments IL-1beta-stimulated lung fluid absorption in fetal guinea pig lungs.
Bhattacharjee, R; Folkesson, HG; Li, T; Nair, PK; Ye, X, 2005
)
1.05
"Metyrapone pre-treated subjects with PVCs had lower HVA and MHPG concentrations."( Catecholamine response to methamphetamine is related to glucocorticoid levels but not to pleasurable subjective response.
Everhart, ET; Harris, DS; Jacob, P; Jones, RT; Mendelson, JE; Reus, VI; Wilson, M; Wolkowitz, O, 2006
)
1.06
"The metyrapone treatment produced no changes in GAD activity at PN23, but induced an important increase in this activity at PN90."( Role of maternal corticosterone in the development and maturation of the aminoacidergic systems of the rat brain.
Garcia-Montojo, M; González, JC; Lecumberri, M; Leret, ML, 2007
)
0.82
"Metyrapone treatment alone caused a 3-fold increase in prostaglandin biosynthesis by fetal adrenal tissues."( Prostaglandin biosynthesis in the human fetal adrenal gland: regulation by glucocorticosteroids.
Carr, BR; Mason, JI; Mitchell, MD; Simpson, ER, 1982
)
0.99
"Metyrapone treatment prolonged the acute release of histamine, and this was seen together with a prolonged acute bronchoconstrictor response."( Allergen-induced late-phase airways obstruction in the pig: mediator release and eosinophil recruitment.
Alving, K; Fornhem, C; Kumlin, M; Lundberg, JM, 1995
)
1.01
"Metyrapone pretreatment blocked the memory-enhancing effects of amphetamine, 4-OH amphetamine, and epinephrine but did not affect retention performance of otherwise untreated animals."( Adrenocortical suppression blocks the memory-enhancing effects of amphetamine and epinephrine.
Carmi, O; McGaugh, JL; Roozendaal, B, 1996
)
1.02
"Metyrapone treatment approximately doubled adrenal weight, which was due to an increase in the area of the definitive, transitional, and fetal zones with decreased cell density of the definitive, transitional, and fetal zones compared with controls and not due to a change in total cell number."( Functional maturation of the primate fetal adrenal in vivo: I. Role of insulin-like growth factors (IGFs), IGF-I receptor, and IGF binding proteins in growth regulation.
Coulter, CL; Goldsmith, PC; Han, VK; Jaffe, RB; Martin, MC; Mesiano, S; Voytek, CC, 1996
)
1.02
"Metyrapone treatment also similarly reduced the response to cocaine and corticosterone secretion in ad libitum-fed controls."( Acute pharmacological blockade of corticosterone secretion reverses food restriction-induced sensitization of the locomotor response to cocaine.
Le Moal, M; Marinelli, M; Piazza, PV, 1996
)
1.02
"Metyrapone pretreatment blocked the pargyline-induced rise in plasma corticosterone to baseline levels and diminished the pargyline-induced increase in 5-HT, without affecting 5-HIAA levels."( Blockade of corticosterone synthesis reduces serotonin turnover in the dorsal hippocampus of the rat as measured by microdialysis.
Bohus, B; De Kloet, ER; Korte, SM; Korte-Bouws, GA, 1996
)
1.02
"Metyrapone treatment partially suppressed cortisol and increased ACTH in castrated calves but did not alter the castration-induced suppression of IFN-gamma and increases in neutrophil numbers and the N:L ratio."( Effects of suppressing cortisol following castration of bull calves on adrenocorticotropic hormone, in vitro interferon-gamma production, leukocytes, acute-phase proteins, growth, and feed intake.
Crowe, MA; Enright, WJ; Fisher, AD; Monaghan, ML; O'Kiely, P; O'Nualláin, EM; Prendiville, DJ, 1997
)
1.02
"Metyrapone pre-treated inferior petrosal sinus sampling is safe, and appears to induce high ACTH output from pituitary corticotroph adenomas. "( Metyrapone pre-treated inferior petrosal sinus sampling in the differential diagnosis of ACTH-dependent Cushing's syndrome.
Atkinson, RL; Cameron, DP; Cuneo, RC; Harper, J; Lee, W; Mitchell, K; Salkield, I; Ward, G, 1997
)
3.18
"Metyrapone-treatment induced a significant drop of plasma corticosterone level and elicited a significant reduction of hypothalamic CRH content, a rise (460%) of the plasma ACTH concentration associated with a significant increase (18%) of the adrenal weight."( Effect of cholinergic blockade on glucocorticoid regulation of NPY and catecholamines in the rat adrenal gland.
Bernet, F; Dupouy, JP; Dutriez-Casteloot, I; Laborie, C; Lesage, J, 1997
)
1.02
"Metyrapone treatment reduced the stress-induced increase in the locomotor, but not stereotypy, response to amphetamine."( Partial reversal of stress-induced behavioral sensitization to amphetamine following metyrapone treatment.
Berger, SP; Ho, LB; Reid, MS; Tolliver, BK; Wolkowitz, OM, 1998
)
1.25
"Such metyrapone pretreatment prevented the increases in serum corticosterone level induced by MK-801."( Impact of metyrapone on MK-801-induced alterations in the rat dopamine D1 receptors.
Chocyk, A; Czyrak, A; Fijał, K; Maćkowiak, M; Wedzony, K,
)
0.99
"The metyrapone treatment morphologically improved the damage provoked by 3 min of ischemia, although it did not alleviate the damage by 5 min."( Metyrapone alleviates ischemic neuronal damage in the gerbil hippocampus.
Adachi, N; Arai, T; Chen, J; Liu, K; Nagaro, T, 1999
)
2.23
"Metyrapone treatment increased the surface expression of CD35 and CD49f on eosinophils, but did not affect surface expression on neutrophils."( Enhanced expression of integrins and CD66b on peripheral blood neutrophils and eosinophils in patients with rheumatoid arthritis, and the effect of glucocorticoids.
Arvidson, NG; Håkansson, L; Hällgren, R; Torsteinsdóttir, I, 1999
)
1.02
"Metyrapone treatment is therefore unlikely to result in the induction of CYP1A1 but may induce the expression of CYP3A4 in humans."( Effect of the adrenal 11-beta-hydroxylase inhibitor metyrapone on human hepatic cytochrome P-450 expression: induction of cytochrome P-450 3A4.
Harvey, JL; Maurel, P; Paine, AJ; Wright, MC, 2000
)
1.28
"Metyrapone pretreatment resulted in statistically significant reductions in UE with steady-state UE averaging 10-14% at 5-200 ppm."( Uptake of styrene in the upper respiratory tract of the CD mouse and Sprague-Dawley rat.
Morris, JB, 2000
)
1.03
"Metyrapone-treatment alone increased the number of eosinophils in the BAL of OVA-challenged mice."( Inhibition of pulmonary eosinophilia and airway hyperresponsiveness in allergic mice by rolipram: involvement of endogenously released corticosterone and catecholamines.
Chapman, RW; Crawley, Y; Kreutner, W; Kung, TT; Luo, B; Young, S, 2000
)
1.03
"Metyrapone pretreatment slightly decreased binding in the Bowman's glands and markedly decreased toxicity in the olfactory mucosa after 2,6-(diCl-MeSO(2)-B) administration."( Target cells for methylsulphonyl-2,6-dichlorobenzene in the olfactory mucosa in mice.
Bahrami, F; Bergman, A; Brandt, I; van Hezik, C, 2000
)
1.03
"Metyrapone pretreatment was effective only to reverse the neutrophilia observed after CTX administration."( Role of crotoxin, a phospholipase A2 isolated from Crotalus durissus terrificus snake venom, on inflammatory and immune reactions.
Cardoso, DF; Faquim-Mauro, EL; Farsky, SH; Lopes-Ferreira, M; Macedo, MS, 2001
)
1.03
"Metyrapone treatment was not found to reduce alcohol consumption more than placebo."( No effect of the cortisol-synthesis inhibitor metyrapone on alcohol drinking: a pilot study.
Balldin, J; Berggren, U; Eriksson, M; Fahlke, C; Hansen, S; Mårin, P, 2001
)
1.29
"The Metyrapone-treated animals developed severe hypertension with greatly elevated serum creatin phosphokinase, glucose, BUN and cholesterol levels."( Metyrapone-induced cardiovascular degenerative changes in non-arteriosclerotic and arteriosclerotic rats.
Greenberg, BP; Wexler, BC, 1978
)
2.18
"Metyrapone pretreatment alone had no significant effect on rCMRglc, but adrenalectomy produced widespread rCMRglc increases in the cortex, hippocampus and monoaminergic brainstem nuclei."( Adrenalectomy or metyrapone-pretreatment abolishes cerebral metabolic responses to the serotonin agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) in the hippocampus.
Freo, U; Holloway, HW; Kalogeras, K; Rapoport, SI; Soncrant, TT, 1992
)
1.34
"Metyrapone treatment resulted in a 28% decrease in the rate of lay and the modal frequency of the time of oviposition was phase-shifted by 15 h."( Effect of metyrapone on the timing of oviposition and ovarian steroidogenesis in the laying hen.
Anderson-Langmuir, CE; Etches, RJ; Petitte, JN, 1991
)
1.41
"Metyrapone treatment resulted in significant atrophy of the uropygial gland with a severe regression of the glandular alveoli due to cytopycnosis, cellular disintegration and drastic cell loss."( Adrenocortical influence on histokinetics and lipid components of uropygial gland of immature chick.
Bandyopadhyay, A; Bhattacharyya, SP; Deadhikari, H; Ranjit, M, 1990
)
1
"The metyrapone treatment also resulted in a decreased or completely inhibited toxicity of dichlobenil to the olfactory mucosa."( Irreversible binding and toxicity of the herbicide dichlobenil (2,6-dichlorobenzonitrile) in the olfactory mucosa of mice.
Bakke, JE; Brandt, I; Brittebo, EB; Feil, VJ, 1990
)
0.76
"Metyrapone treatment, 1.5 g, increased the half-life of acetaminophen, decreased the fraction of the dose recovered in the urine as the glucuronide and increased the fraction of the dose recovered in urine as the sulfate and mercapturate conjugates."( Pharmacokinetic consequences and toxicologic implications of metyrapone-induced alterations of acetaminophen elimination in man.
Galinsky, RE; Nelson, EB; Rollins, DE, 1987
)
1.24
"Metyrapone treatment greatly reduced all agonistic behaviors, groups of fish forming shoals typical of juveniles."( Steroid hormones and agonistic behavior in a cichlid teleost, Aequidens pulcher.
Munro, AD; Pitcher, TJ, 1985
)
0.99
"Treatment in metyrapone, an inhibitor of 11β-hydroxylase, significantly inhibited cortisol production and resulted in the inability of the fish to appropriately transition to exogenous feeding."( Endogenous cortisol production and its relationship with feeding transitions in larval lake sturgeon (Acipenser fulvescens).
Ali, JL; Anderson, WG; Bugg, WS; Earhart, ML; Jeffries, KM, 2020
)
0.91
"Treatment with metyrapone was started before pituitary surgery."( Pneumocystis pneumonia can complicate medical treatment of hypercortisolism even in outpatients with Cushing's disease.
Carreau, A; Chabre, O; Cristante, J; Lepelley, M; Mallaret, M, 2020
)
0.9
"Pretreatment with metyrapone, oxazepam and their combinations in intact rats resulted in a significant decrease in cocaine-reinforced responses."( The extra-adrenal effects of metyrapone and oxazepam on ongoing cocaine self-administration.
Goeders, NE; Guerin, GF; Schmoutz, CD, 2014
)
1.02
"Pretreatment by metyrapone, the inhibitor of glucocorticoid synthesis was the most suitable approach because of a short-lasting inhibiting effect of the drug."( [Metyrapone effect on gastroprotective action of corticotropin-releasing factor administered centrally against indomethacin-induced gastric injury].
Bagaeva, TR; Filaretova, LP; Miazina, MA, 2014
)
1.65
"Pretreatment with metyrapone decreased freezing and Fos expression in these areas."( Rapid Activation of Glucocorticoid Receptors in the Prefrontal Cortex Mediates the Expression of Contextual Conditioned Fear in Rats.
Almada, RC; Brandão, ML; Fogaça, MV; Reis, FM, 2016
)
0.76
"Treatment with metyrapone led to a swift improvement of the patient's symptoms."( [Cushing's syndrome in a manic patient with a long-standing bipolar disorder: cause or coincidence?].
Bartel, M; de Witte, LD; Kleijweg, M; Smits, RB; Valk, GD; Vergeer, M; Vinkers, CH, 2015
)
0.76
"Pretreatment with metyrapone inhibited the increase in plasma corticosterone levels induced by the bite-raised condition, and also attenuated the reduction in cell proliferation."( Chewing under restraint stress inhibits the stress-induced suppression of cell birth in the dentate gyrus of aged SAMP8 mice.
Karasawa, N; Kubo, KY; Ono, Y; Onozuka, M; Sasaguri, K; Takahashi, T; Watanabe, K; Yamamoto, T, 2009
)
0.68
"Pretreatment with metyrapone (100 m a g , intraperitoneal)1 h before inescapable stress (40 2mA tail shocks delivered over a 1-h period) (IS)blocked the acute plasma corticosterone response to IS."( Pharmacological suppression of corticosterone secretion in response to a physical stressor does not prevent the delayed persistent increase in circulating basal corticosterone concentration.
Beck, KD; Beldowicz, D; Brennan, FX; Moldow, RL; Ottenweller, JE; Servatius, RJ; Zhug, G, 2001
)
0.63
"Pretreatment with metyrapone counteracted effects produced by LPS, including hormonal and behavioral responses in lactating rats."( Corticosterone synthesis inhibitor metyrapone preserves changes in maternal behavior and neuroendocrine responses during immunological challenge in lactating rats.
Antunes-Rodrigues, J; Elias, LL; Giusti-Paiva, A; Vilela, FC, 2013
)
0.99
"Treatment with metyrapone could be recommended, for some patients, in McCune-Albright syndrome with Cushing's syndrome before chirurgical treatment."( [Treatment with metyrapone of Cushing's syndrome revealing McCune-Albright syndrome].
Azzabi, O; Ben Ammar, B; Ben Hariz, M; Ben Mrad, N; Halioui-Louhaichi, S; Maherzi, A; Nefzi, L, 2005
)
1.03
"Pretreatment with metyrapone increased the rate of metabolism of the hydrocarbon mainly by increasing the amounts of products resulting from hydroxylation of the methyl groups: small increases in the amounts of ring-hydroxylated products were also produced."( The effect of pretreatment with adrenal-protecting compounds on the metabolism of 7,12-dimethylbenz[a]anthracene and related compounds by rat-liver homogenates.
Boyland, E; Sims, P, 1967
)
0.57
"Pretreatment with metyrapone accelerated both antigen-induced responses."( Effect of ZCR-2060, an antiallergic agent, on antigen-induced immediate- and late-phase increases in airway resistance in sensitized guinea pigs.
Abe, T; Matsuda, K; Nagai, H; Omata, T; Segawa, Y; Yoshida, K, 1995
)
0.61
"Pretreatment with metyrapone (300 mg/kg) was found to delay the Se-induced rise in plasma glucose."( Effect of selenium (Se) on plasma ACTH, beta-endorphin, corticosterone and glucose in rat: influence of adrenal enucleation and metyrapone pretreatment.
Early, JL; Nonavinakere, VK; Potmis, RA; Rasekh, HR, 1993
)
0.81
"Pigs treated with metyrapone had greater (P < .05) numbers of neutrophils than control pigs."( In vivo glucocorticoid effects on porcine natural killer cell activity and circulating leukocytes.
McGlone, JJ; Norman, RL; Salak-Johnson, JL, 1996
)
0.62
"Treatment with metyrapone resulted in greatly increased urinary excretion of 11-deoxy corticosteroids, including the GABA-modulatory steroid tetrahydro-11-deoxycorticosterone (from 68 +/- 34 to 219 +/- 75 micrograms/24 h, p < .05)."( The relationship between the effects of metyrapone treatment on depressed mood and urinary steroid profiles.
Checkley, SA; O'Dwyer, AM; Raven, PW; Taylor, NF, 1996
)
0.9
"Treatment with metyrapone totally abolished these effects."( Acute pharmacological blockade of corticosterone secretion reverses food restriction-induced sensitization of the locomotor response to cocaine.
Le Moal, M; Marinelli, M; Piazza, PV, 1996
)
0.63
"Treatment with metyrapone significantly increased eosinophil infiltration (17.4 +/- 9.93 x 10(3) and 18.7 +/- 2.57 x 10(3) cells, P < 0.05 at 3 h and 24 h, respectively) and potentiated airway hyperresponsiveness to methacholine compared to vehicle-treated ovalbumin-challenged animals."( Effect of dexamethasone and endogenous corticosterone on airway hyperresponsiveness and eosinophilia in the mouse.
De Bie, JJ; Hessel, EM; Hofman, G; Nijkamp, FP; Van Ark, I; Van Esch, B; Van Oosterhout, AJ, 1996
)
0.63
"Treatment with metyrapone enhanced the spontaneous nocturnal prolactin surge and also the prolactin response to D-fenfluramine."( The influence of cortisol on spontaneous and 5HT stimulated prolactin release in man.
Dinan, TG; Scott, LV, 1996
)
0.63
"pretreatment with metyrapone for 3 days failed to attenuate phase 1."( Acetylcholine-induced systemic vasodilation resistant to NG-nitro-L-arginine in an anaesthetized rats.
Kakizoe, E; Kobayashi, Y; Okunishi, H; Shimoura, K; Wang, DQ,
)
0.45
"Pretreatment with metyrapone (12.5 or 25 mg/kg, s.c.) 90 min beforehand dose-dependently blocked the enhancement of memory storage and of the plasma corticosterone level produced by psychological stress."( Adrenocortical suppression blocks the enhancement of memory storage produced by exposure to psychological stress in rats.
Liu, L; Matsumiya, T; Takada, K; Takeda, H; Tsuji, M, 1999
)
0.63
"Treatment with metyrapone appeared to stabilize the cat metabolically and clinically prior to surgery."( Hyperadrenocorticism treated with metyrapone followed by bilateral adrenalectomy in a cat.
Biller, DS; Moore, LE; Olsen, DE, 2000
)
0.93
"Pretreatment with metyrapone (12.5 and 25 mg kg(-1), s.c.) partly antagonized the protective effects of flesinoxan (1 mg kg(-1), i.p.) and 8-OH-DPAT (1 mg kg(-1), i.p.) with regard to only the number and duration of head-dipping behaviours."( Protective effects of 5-HT1A receptor agonists against emotional changes produced by stress stimuli are related to their neuroendocrine effects.
Matsumiya, T; Takeda, H; Tsuji, M, 2001
)
0.63
"Pretreatment with metyrapone, which suppresses the stress-induced rise in plasma corticosterone levels, prevented the molarless condition-induced increase in plasma corticosterone levels, reduction in CA1 pyramidal neuron numbers, and impairment of spatial learning."( Evidence for involvement of glucocorticoid response in the hippocampal changes in aged molarless SAMP8 mice.
Fujita, M; Onozuka, M; Saito, S; Tonosaki, K; Watanabe, K, 2002
)
0.64
"Treatment with metyrapone thus appears a good therapy for AIMAH, but its effectiveness has not, to our knowledge, been studied."( Rational, effective metyrapone treatment of ACTH-independent bilateral macronodular adrenocortical hyperplasia (AIMAH).
Nomura, K; Obara, T; Omori, K; Omori, N; Takano, K, 2001
)
0.97
"Pretreatment with metyrapone provoked a hypersecretion of FSH following a single injection of synthetic LRH."( The effect of prednisolone and metyrapone on FSH release induced by the administration of LRH.
Sakakura, M; Takebe, K; Yoshioka, M, 1978
)
0.87
"Treatment with metyrapone decreased her cortisol production and produced clinical remission of Cushing's syndrome."( The immunological hazard of Cushing's syndrome.
Britton, S; Sjoberg, HE; Thorén, M, 1975
)
0.59
"Pretreatment with metyrapone for one day (4.5 g/sugject injection of synthetic LRH (0.1 MG/SUBJECT)."( Inhibition of luteinizing hormone secretion induced by synthetic LRH by long-term treatment with glucocorticoids in human subjects.
Nakagawa, S; Sakakura, M; Takebe, K, 1975
)
0.58
"Treatment with metyrapone (30 mg/kg, i.m.), an inhibitor of adrenal steroidogenesis that prevented the CRF-induced rise in serum cortisol levels, did not reverse the inhibitory effects of CRF on the frequency or duration of MUA volleys."( Corticotropin-releasing factor and gonadotropin-releasing hormone pulse generator activity in the rhesus monkey. Electrophysiological studies.
Grosser, PM; Hotchkiss, J; Knobil, E; Nishihara, M; Thalabard, JC; Williams, CL, 1990
)
0.62
"Pretreatment with metyrapone, an 11-beta-hydroxylase blocker, (80 mg/kg, im) 4 hr before salt loading did not effect the volume of salt gland secretion but delayed the onset of extrarenal excretion."( Independence of salt gland function and adrenocortical activity in ducks (Anas platyrhynchos).
Harvey, S; Phillips, JG; Rees, A, 1985
)
0.59
"Treatment with metyrapone or o,p'-DDD can always induce a clinical remission but not a cure, and neurotransmitter therapy may be effective in a minority of cases."( Cushing's syndrome.
Besser, GM; Howlett, TA; Rees, LH, 1985
)
0.61
"Pre-treatment of metyrapone, an inhibitor of adrenocortical steroid biosynthesis, had an effect that was similar to, but far weaker than that of Adx on stressed mice."( Stress and immune responses. IV. Adrenal involvement in the alteration of antibody responses in restraint-stressed mice.
Ogawa, M; Okimura, T; Sasaki, Y; Yamauchi, T, 1986
)
0.6
"Pretreatment with metyrapone before a 0.14-mumol/kg i.v."( Effects of metyrapone on the pharmacological activity, plasma levels and urinary excretion of the dopamine receptor agonist DK-118.
Cannon, JG; Fischer, LJ; Koble, DL; Koons, JC; Long, JP, 1985
)
0.98
"Pretreatment with metyrapone (a corticosterone synthesis inhibitor 150 mg/kg i.p., 3 h before each immobilisation) did not affect the above responses to 1 immobilisation, increased tremor after 3 immobilisations and also increased forepaw treading, hind limb abduction and Straub tail after 7 immobilisations but decreased head weaving under the latter conditions."( Central serotonergic responses and behavioural adaptation to repeated immobilisation: the effect of the corticosterone synthesis inhibitor metyrapone.
Curzon, G; Dickinson, SL; Kennett, GA, 1985
)
0.79

Toxicity

The concentration-dependent protection from methapyrilene toxicity afforded by metyrapone correlated with an inhibition of microsomal CYP2C11-associated androstenedione 16alpha hydroxylase activity. This review will rather focus specifically on adverse events associated with these drugs (ketoconazole, levoketoconazoles, metYrapone, osilodrostat, pasireotide, cabergoline and mifepristone)

ExcerptReferenceRelevance
" The present study was undertaken to study the toxic effect of AFB1 on hepatocyte and RNA synthesis, and to assess the influence of the inhibitors on AFB1-induced cytotoxicity and AFB1-inhibited RNA synthesis."( Effect of inhibitors of microsomal enzymes on aflatoxin B1-induced cytotoxicity and inhibition of RNA synthesis in isolated rat hepatocytes.
Ch'ih, JJ; Devlin, TM; Lin, T, 1983
)
0.27
" The concentration-dependent protection from methapyrilene toxicity afforded by metyrapone correlated with an inhibition of microsomal CYP2C11-associated androstenedione 16alpha hydroxylase activity, and hepatocytes prepared from hypophysectomised rats (containing reduced levels of microsomal immunodetectable CYP2C11 and associated androstenedione 16alpha hydroxylase activity) showed resistance to the toxic effects of methapyrilene."( Methapyrilene hepatotoxicity is associated with oxidative stress, mitochondrial disfunction and is prevented by the Ca2+ channel blocker verapamil.
Morgan, WA; Mullervy, J; Powell, CJ; Ratra, GS; Wright, MC, 1998
)
0.53
" (GSH) appears to act as a non-enzymatic reductant, reducing Cr(VI) to a toxic form."( The role of glutathione reductase in the cytotoxicity of chromium (VI) in isolated rat hepatocytes.
Grant, MH; Gunaratnam, M, 2001
)
0.31
" At equimolar concentrations (1 mM) BHT was the most toxic of the three compounds, causing an 80% decrease in cell viability over a 6 h incubation period."( Comparative metabolism, covalent binding and toxicity of BHT congeners in rat liver slices.
Fujiwara, H; Reed, M; Thompson, DC, 2001
)
0.31
"Striking parallels exist between the neurochemical and toxic effects of stress and methamphetamine."( Chronic stress enhances methamphetamine-induced extracellular glutamate and excitotoxicity in the rat striatum.
Tata, DA; Yamamoto, BK, 2008
)
0.35
" This review will rather focus specifically on adverse events associated with these drugs (ketoconazole, levoketoconazole, metyrapone, osilodrostat, pasireotide, cabergoline and mifepristone), and the way in which to monitor and treat them, based on retrospective studies and the most recently published prospective studies."( How best to monitor the specific side effects of medical treatments of Cushing's disease.
Castinetti, F, 2022
)
0.93

Pharmacokinetics

ExcerptReferenceRelevance
" The present pharmacokinetic study investigates the potential for modulation of these alternative pathways of IF metabolism in vivo using the adult male Fischer 344 rat model."( Modulation of P450-dependent ifosfamide pharmacokinetics: a better understanding of drug activation in vivo.
Brain, EG; Drewes, P; Gustafsson, K; Waxman, DJ; Yu, LJ, 1998
)
0.3
" Blood concentrations versus time profile for each compound was determined and the pharmacokinetic parameters calculated using the model-independent approach."( Pharmacokinetics of 2-methoxyphenylmetyrapone and 2-bromophenylmetyrapone in rats.
Damani, LA; Lin, G; Mitterhauser, M; Nnane, IP; Tsai, MC; Zolle, I,
)
0.41
" We also measured pharmacokinetic parameters: the level of IMI and its metabolite, desipramine (DMI), in the rat plasma and brain (1 h after the forced swimming test)."( Effects of combined treatment with imipramine and metyrapone in the forced swimming test in rats. Behavioral and pharmacokinetic studies.
Daniel, WA; Rogóz, Z; Skuza, G; Wójcikowski, J,
)
0.38

Bioavailability

The effects of methimazole (MTZ), metyrapone (MTP) and quinine (QNE) on the pharmacokinetics and bioavailability of netobimin (NTB) and its major metabolites were studied in sheep.

ExcerptReferenceRelevance
"The effects of methimazole (MTZ), metyrapone (MTP) and quinine (QNE) on the pharmacokinetics and bioavailability of parenterally administered netobimin (NTB) and its major metabolites, albendazole sulphoxide (ABZSO) and albendazole sulphone (ABZSO2), were studied in sheep."( Enhancement of the plasma concentration of albendazole sulphoxide in sheep following coadministration of parenteral netobimin and liver oxidase inhibitors.
Lanusse, CE; Prichard, RK, 1991
)
0.56
" We conclude that, in addition to decreased cortisol synthesis, increased secretion of cortisol precursors and reduced local bioavailability of cortisol may play a role in the antidepressant effect of metyrapone."( The relationship between the effects of metyrapone treatment on depressed mood and urinary steroid profiles.
Checkley, SA; O'Dwyer, AM; Raven, PW; Taylor, NF, 1996
)
0.75
"Biotransformation in the intestine may influence the bioavailability and toxicity of ingested xenobiotics."( Properties and regional expression of a CYP3A-like protein in channel catfish intestine.
Celander, MC; James, MO; Lou, Z; Rowland-Faux, L, 2005
)
0.33
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Metyrapone was administered orally at a dosage of 65 mg/kg of body weight. The effects of cytochrome P-450 inhibitor [2-dimethylaminoethyl-2,2-diphenyl-n-pentanoate (SKF-525A) and metyrapone] on the response of rabbit aortic rings to GTN was determined.

ExcerptRelevanceReference
" dosage on 4 hours, this is a rapid test able to put in combination other hypophysal tests."( [Changes in plasma level of corticotropin after intravenous injection of metyrapone. Value of this test in pituitary pathology].
Gabaude, B; Huguenin, A; Javalet, A; Murie, N, 1977
)
0.49
" This dosage resulted in partial adrenal suppression, manifested by reduced levels of plasma cortisol."( Topical corticosteroid therapy and pituitary-adrenal function.
Becker, B; Krupin, T; Mandell, AI; Podos, SM, 1976
)
0.26
"This study defines the pituitary B-endorphin (BE) secretory response to a low dosage (0."( B-endorphin response to a low dosage of human corticotropin releasing hormone during metyrapone administration in depression.
Brazis, M; Dorin, R; Hauger, R; Lisansky, J; Meikle, AW; Qualls, C; Strassman, R; Turkin, A, 1992
)
0.51
" To further explore the link between the HPA and the immune system in relation to glucocorticoid receptor function, dose-response curves were obtained for Con A- and PHA-induced T-cell mitogenesis, PWM-generated B-cell mitogenesis and spontaneous lymphocyte proliferation in 13 healthy controls."( In vivo and in vitro effects of glucocorticoids on lymphocyte proliferation in man: relationship to glucocorticoid receptors.
Braner, HU; Kornhuber, J; Müller, OA; Riederer, P; Rupprecht, R; Schmitz, B; Wild, K; Wodarz, N,
)
0.13
" When the ambient cortisol level was equalized (and suppressed) in all subjects at the time of study with a threshold dosage of corticotropin-releasing hormone, we found an augmented response to corticotropin-releasing hormone in depressives."( Augmented pituitary corticotropin response to a threshold dosage of human corticotropin-releasing hormone in depressives pretreated with metyrapone.
Britton, D; Fava, GA; Hochla, P; Lisansky, J; Meikle, AW; Peake, GT; Qualls, C; Risch, SC; Strassman, RJ; Zownir-Brazis, M, 1989
)
0.48
" We suggest that, in children being treated with ACTH, the dosage of ACTH should be gradually tapered, AM cortisol levels should be monitored, and high-dose steroids should be included when treating medical stress."( Hypothalamo-pituitary-adrenal function in infantile spasms: effects of ACTH therapy.
Rao, JK; Willis, J, 1987
)
0.27
"This study was undertaken to examine the role of adrenal androgen excess in the pathogenesis of polycystic ovary syndrome (PCOS) and, if such was present, to assess its reversibility using dexamethasone given in physiological dosage at night."( Adrenal abnormalities in polycystic ovary syndrome.
Culliton, M; Cunningham, S; Loughlin, T; McKenna, TJ; Moore, A; Smyth, PP, 1986
)
0.27
" In each of three repeated measures, females given an intermediate dosage (800 micrograms/animal/injection) showed substantially higher levels of receptivity than those given vehicle injections or other dosages."( Facilitation of sexual receptivity in female mice through blockade of adrenal 11 beta-hydroxylase.
de Catanzaro, D; Kerr, TH; Lee, PC, 1985
)
0.27
" To eliminate ACTH-dependent steroid synthesis, the experiments were performed in subjects receiving constant dosage of dexamethasone."( Site of stimulation of aldosterone biosynthesis by angiotensin and potassium.
Brown, RD; Liddle, GW; Strott, CA, 1972
)
0.25
" A marked clinical and laboratory improvement was noted in two patients, in another some clinical and laboratory improvement was obtained only after bromocriptine dosage was increased to 15 mg/day."( Cushing's disease: clinical and laboratory response to bromocriptine therapy.
Antunes, RC; de Pinho, MO; Francalanci, CC; Franco, S; Lima, MB, 1984
)
0.27
" S with an ACTH-cortisol dose-response curve obtained in normal subjects shows that subnormal ACTH responses after metyrapone in the range between 13 and 33 pmol/L still generate normal comp."( Pituitary function tests: comparison of ACTH and 11-deoxy-cortisol responses in the metyrapone test and with the insulin hypoglycemia test.
Bähr, V; Exner, P; Oelkers, PW; Steiner, H, 1994
)
0.72
" The effects of cytochrome P-450 inhibitor [2-dimethylaminoethyl-2,2-diphenyl-n-pentanoate (SKF-525A) and metyrapone] on the response of rabbit aortic rings to GTN was determined by recording cumulative GTN dose-response curves in the presence of either or both inhibitors."( Lack of evidence for the involvement of cytochrome P-450 or other hemoproteins in metabolic activation of glyceryl trinitrate in rabbit aorta.
Brien, JF; Liu, Z; Marks, GS; McLaughlin, BE; Nakatsu, K, 1993
)
0.5
" Metyrapone was administered orally at a dosage of 65 mg/kg of body weight, every 12 hours."( Use of metyrapone to treat pituitary-dependent hyperadrenocorticism in a cat with large cutaneous wounds.
Daley, CA; Powers, RD; Schick, RO; Zerbe, CA, 1993
)
1.65
" Both the U-shaped dose-response curve seen with buspirone in some animal tests of anxiety and its slow onset of clinical action could be attributed to this release of stress hormones."( The pituitary-adrenal axis and the different behavioral effects of buspirone and chlordiazepoxide.
Logan, B; McNaughton, N; Panickar, KS, 1996
)
0.29
" Chromatographic and mass analysis of urinary extracts from rats dosed with 2-MPMP have confirmed the major metabolites as 2-hydroxyphenylmetyrapone (2-OHPMP), 2) and its N-oxide (2-OHPMP-NO, 6), which are present predominantly as conjugates."( Spectral and chromatographic properties of 2-methoxyphenylmetyrapone and its potential metabolites.
Damani, LA; Ho, YP; Lin, G; Mitterhauser, M; Zolle, I, 1997
)
0.74
" In a final experiment, a dose-response study of metyrapone-induced FLI was carried out focusing on selected brain areas."( Evidence that metyrapone can act as a stressor: effect on pituitary-adrenal hormones, plasma glucose and brain c-fos induction.
Armario, A; Carrasco, J; Ons, S; Rotllant, D, 2002
)
0.93
" Stimulation of adrenal CMP-S and cortisol by pituitary ACTH demonstrated a dose-response curve with the shape of half a geometric parabola."( Combined stimulation of adrenocorticotropin and compound-S by single dose metyrapone test as an outpatient procedure to assess hypothalamic-pituitary-adrenal function.
Berneis, K; Gessler, A; Girard, J; Meier, C; Müller, B; Staub, JJ, 2002
)
0.55
" Whenever possible, dosage reduction or treatment withdrawal should be considered as soon as possible depending on the underlying disease being treated."( [How to plan glucocorticoid withdrawal: diagnostic and therapeutic strategies].
Vollenweider, P; Waeber, G, 2003
)
0.32
" Dose-response studies using metyrapone and glucocorticoid agonists are needed to further investigate HPA axis regulation in PTSD."( Overnight metyrapone and combined dexamethasone/metyrapone tests in post-traumatic stress disorder: preliminary findings.
Jahn, H; Kellner, M; Otte, C; Schick, M; Wiedemann, K; Yassouridis, A, 2004
)
1.02
" This dosing regimen also produces deficits in sequential learning as measured in the Cincinnati water maze (CWM)."( Metyrapone attenuates the sequential learning deficits but not monoamine depletions following d,l-fenfluramine administration to adult rats.
Blankenmeyer, TL; Brown-Strittholt, CA; Gudelsky, GA; Skelton, MR; Vorhees, CV; Williams, MT, 2004
)
1.77
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
"Startle responses were measured in 64 male Wistar rats while varying startling stimulus intensities, analogous to dose-response curves."( Corticosteroid dependent and independent effects of a cannabinoid agonist on core temperature, motor activity, and prepulse inhibition of the acoustic startle reflex in Wistar rats.
Avdesh, A; Cornelisse, V; Martin-Iverson, MT, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
diagnostic agentA substance administered to aid diagnosis of a disease.
antimetaboliteA substance which is structurally similar to a metabolite but which competes with it or replaces it, and so prevents or reduces its normal utilization.
EC 1.14.15.4 (steroid 11beta-monooxygenase) inhibitorAn EC 1.14.15.* (oxidoreductase acting on paired donors, with reduced iron-sulfur protein as one donor, incorporating 1 atom of oxygen) inhibitor that interferes with the action of steroid 11beta-monooxygenase (EC 1.14.15.4).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
aromatic ketoneA ketone in which the carbonyl group is attached to an aromatic ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (8)

PathwayProteinsCompounds
chelerythrine biosynthesis1024
rosmarinic acid biosynthesis I130
superpathway of rosmarinic acid biosynthesis140
sanguinarine and macarpine biosynthesis639
sesamin biosynthesis013
sesamin biosynthesis015
rosmarinic acid biosynthesis I334
chelerythrine biosynthesis823
sanguinarine and macarpine biosynthesis839
superpathway of rosmarinic acid biosynthesis243
trans-zeatin biosynthesis721
abietic acid biosynthesis416
superpathway of diterpene resin acids biosynthesis443

Protein Targets (36)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency22.38720.004023.8416100.0000AID485290
thioredoxin reductaseRattus norvegicus (Norway rat)Potency31.62280.100020.879379.4328AID588453
GALC proteinHomo sapiens (human)Potency0.707928.183828.183828.1838AID1159614
GLI family zinc finger 3Homo sapiens (human)Potency0.11880.000714.592883.7951AID1259369
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency7.76190.01237.983543.2770AID1645841
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency1.25890.031610.279239.8107AID884; AID885
lamin isoform A-delta10Homo sapiens (human)Potency7.94330.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)229.00000.11007.190310.0000AID1449628
Steroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)IC50 (µMol)10.00000.00200.98184.7300AID499539
Cytochrome P450 1A2Homo sapiens (human)IC50 (µMol)4.80000.00011.774010.0000AID1449098; AID1449131
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)2.86590.00011.753610.0000AID428564; AID625251
Cytochrome P450 2C8Homo sapiens (human)IC50 (µMol)5.00000.00081.88487.9000AID1449131
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)4.60000.00002.015110.0000AID1449098
AromataseHomo sapiens (human)IC50 (µMol)5.00000.00001.290410.0000AID1203963
Cytochrome P450 11B1, mitochondrial Bos taurus (cattle)IC50 (µMol)7.83000.00101.06087.8300AID3091
Cytochrome P450 11B1, mitochondrialRattus norvegicus (Norway rat)IC50 (µMol)4.73570.49503.52895.0000AID1203964; AID1449098; AID1449131
Cytochrome P450 11B1, mitochondrialHomo sapiens (human)IC50 (µMol)0.01810.00050.29022.7800AID1162191; AID1174181; AID1177643; AID1203961; AID1402018; AID1449095; AID549715; AID553065; AID652428; AID765522
Cytochrome P450 11B2, mitochondrialHomo sapiens (human)IC50 (µMol)0.08380.00010.27383.5000AID1162198; AID1174182; AID1177642; AID1203962; AID1449096; AID549714; AID553066; AID652429; AID765521
Cytochrome P450 2C19Homo sapiens (human)IC50 (µMol)5.00000.00002.398310.0000AID1449131
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (97)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
steroid biosynthetic processSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
androgen biosynthetic processSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
glucocorticoid biosynthetic processSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
sex differentiationSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
steroid metabolic processSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
hormone biosynthetic processSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
progesterone metabolic processSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
lipid hydroxylationCytochrome P450 2C8Homo sapiens (human)
organic acid metabolic processCytochrome P450 2C8Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C8Homo sapiens (human)
steroid metabolic processCytochrome P450 2C8Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C8Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C8Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C8Homo sapiens (human)
retinol metabolic processCytochrome P450 2C8Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 2C8Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C8Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C8Homo sapiens (human)
oxidative demethylationCytochrome P450 2C8Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C8Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of chronic inflammatory responseAromataseHomo sapiens (human)
steroid biosynthetic processAromataseHomo sapiens (human)
estrogen biosynthetic processAromataseHomo sapiens (human)
androgen catabolic processAromataseHomo sapiens (human)
syncytium formationAromataseHomo sapiens (human)
negative regulation of macrophage chemotaxisAromataseHomo sapiens (human)
sterol metabolic processAromataseHomo sapiens (human)
female genitalia developmentAromataseHomo sapiens (human)
mammary gland developmentAromataseHomo sapiens (human)
uterus developmentAromataseHomo sapiens (human)
prostate gland growthAromataseHomo sapiens (human)
testosterone biosynthetic processAromataseHomo sapiens (human)
positive regulation of estradiol secretionAromataseHomo sapiens (human)
female gonad developmentAromataseHomo sapiens (human)
response to estradiolAromataseHomo sapiens (human)
glucocorticoid biosynthetic processCytochrome P450 11B1, mitochondrial Bos taurus (cattle)
C21-steroid hormone biosynthetic processCytochrome P450 11B1, mitochondrialHomo sapiens (human)
glucocorticoid biosynthetic processCytochrome P450 11B1, mitochondrialHomo sapiens (human)
immune responseCytochrome P450 11B1, mitochondrialHomo sapiens (human)
regulation of blood pressureCytochrome P450 11B1, mitochondrialHomo sapiens (human)
sterol metabolic processCytochrome P450 11B1, mitochondrialHomo sapiens (human)
aldosterone biosynthetic processCytochrome P450 11B1, mitochondrialHomo sapiens (human)
cellular response to hormone stimulusCytochrome P450 11B1, mitochondrialHomo sapiens (human)
cortisol biosynthetic processCytochrome P450 11B1, mitochondrialHomo sapiens (human)
cellular response to potassium ionCytochrome P450 11B1, mitochondrialHomo sapiens (human)
glucose homeostasisCytochrome P450 11B1, mitochondrialHomo sapiens (human)
cholesterol metabolic processCytochrome P450 11B1, mitochondrialHomo sapiens (human)
cortisol metabolic processCytochrome P450 11B1, mitochondrialHomo sapiens (human)
cellular response to peptide hormone stimulusCytochrome P450 11B1, mitochondrialHomo sapiens (human)
cortisol biosynthetic processCytochrome P450 11B2, mitochondrialHomo sapiens (human)
regulation of blood volume by renal aldosteroneCytochrome P450 11B2, mitochondrialHomo sapiens (human)
renal water homeostasisCytochrome P450 11B2, mitochondrialHomo sapiens (human)
C21-steroid hormone biosynthetic processCytochrome P450 11B2, mitochondrialHomo sapiens (human)
mineralocorticoid biosynthetic processCytochrome P450 11B2, mitochondrialHomo sapiens (human)
sterol metabolic processCytochrome P450 11B2, mitochondrialHomo sapiens (human)
aldosterone biosynthetic processCytochrome P450 11B2, mitochondrialHomo sapiens (human)
cellular response to hormone stimulusCytochrome P450 11B2, mitochondrialHomo sapiens (human)
cortisol biosynthetic processCytochrome P450 11B2, mitochondrialHomo sapiens (human)
cellular response to potassium ionCytochrome P450 11B2, mitochondrialHomo sapiens (human)
potassium ion homeostasisCytochrome P450 11B2, mitochondrialHomo sapiens (human)
sodium ion homeostasisCytochrome P450 11B2, mitochondrialHomo sapiens (human)
glucocorticoid biosynthetic processCytochrome P450 11B2, mitochondrialHomo sapiens (human)
cortisol metabolic processCytochrome P450 11B2, mitochondrialHomo sapiens (human)
cellular response to peptide hormone stimulusCytochrome P450 11B2, mitochondrialHomo sapiens (human)
cholesterol metabolic processCytochrome P450 11B2, mitochondrialHomo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 2C19Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C19Homo sapiens (human)
steroid metabolic processCytochrome P450 2C19Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C19Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C19Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (43)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
steroid 17-alpha-monooxygenase activitySteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
iron ion bindingSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
oxygen bindingSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
heme bindingSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
17-alpha-hydroxyprogesterone aldolase activitySteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
monooxygenase activityCytochrome P450 2C8Homo sapiens (human)
iron ion bindingCytochrome P450 2C8Homo sapiens (human)
protein bindingCytochrome P450 2C8Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C8Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 2C8Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C8Homo sapiens (human)
aromatase activityCytochrome P450 2C8Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 2C8Homo sapiens (human)
heme bindingCytochrome P450 2C8Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C8Homo sapiens (human)
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingAromataseHomo sapiens (human)
steroid hydroxylase activityAromataseHomo sapiens (human)
electron transfer activityAromataseHomo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenAromataseHomo sapiens (human)
oxygen bindingAromataseHomo sapiens (human)
heme bindingAromataseHomo sapiens (human)
aromatase activityAromataseHomo sapiens (human)
iron ion bindingCytochrome P450 11B1, mitochondrial Bos taurus (cattle)
heme bindingCytochrome P450 11B1, mitochondrial Bos taurus (cattle)
steroid 11-beta-monooxygenase activityCytochrome P450 11B1, mitochondrialHomo sapiens (human)
iron ion bindingCytochrome P450 11B1, mitochondrialHomo sapiens (human)
heme bindingCytochrome P450 11B1, mitochondrialHomo sapiens (human)
corticosterone 18-monooxygenase activityCytochrome P450 11B1, mitochondrialHomo sapiens (human)
steroid 11-beta-monooxygenase activityCytochrome P450 11B2, mitochondrialHomo sapiens (human)
iron ion bindingCytochrome P450 11B2, mitochondrialHomo sapiens (human)
steroid hydroxylase activityCytochrome P450 11B2, mitochondrialHomo sapiens (human)
heme bindingCytochrome P450 11B2, mitochondrialHomo sapiens (human)
corticosterone 18-monooxygenase activityCytochrome P450 11B2, mitochondrialHomo sapiens (human)
monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
iron ion bindingCytochrome P450 2C19Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxygen bindingCytochrome P450 2C19Homo sapiens (human)
enzyme bindingCytochrome P450 2C19Homo sapiens (human)
heme bindingCytochrome P450 2C19Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
aromatase activityCytochrome P450 2C19Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C19Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (20)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
endoplasmic reticulumSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
endoplasmic reticulum membraneSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
axonSteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
neuronal cell bodySteroid 17-alpha-hydroxylase/17,20 lyaseHomo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C8Homo sapiens (human)
plasma membraneCytochrome P450 2C8Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C8Homo sapiens (human)
cytoplasmCytochrome P450 2C8Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C8Homo sapiens (human)
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumAromataseHomo sapiens (human)
endoplasmic reticulum membraneAromataseHomo sapiens (human)
membraneAromataseHomo sapiens (human)
endoplasmic reticulumAromataseHomo sapiens (human)
mitochondrionCytochrome P450 11B1, mitochondrialHomo sapiens (human)
mitochondrial inner membraneCytochrome P450 11B1, mitochondrialHomo sapiens (human)
mitochondrial inner membraneCytochrome P450 11B1, mitochondrialHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
mitochondrionCytochrome P450 11B2, mitochondrialHomo sapiens (human)
mitochondrial inner membraneCytochrome P450 11B2, mitochondrialHomo sapiens (human)
mitochondrial inner membraneCytochrome P450 11B2, mitochondrialHomo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C19Homo sapiens (human)
plasma membraneCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
cytoplasmCytochrome P450 2C19Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (155)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1134142Inhibition of bovine adrenal gland 11beta-hydroxylase assessed as inhibition of [14C]-deoxycorticosterone hydroxylation at 2 uM relative to metyrapone1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
New inhibitors of steroid 11beta-hydroxylase. Structure--activity relationship studies of metyrapone-like compounds.
AID499539Inhibition of human CYP17 expressed in Escherichia coli2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.
AID1449096Inhibition of human CYP11B2 expressed in hamster V79MZ cells using [1,2-3H]-11-deoxycorticosterone as substrate after 6 hrs by HPLC analysis2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Lead Optimization Generates CYP11B1 Inhibitors of Pyridylmethyl Isoxazole Type with Improved Pharmacological Profile for the Treatment of Cushing's Disease.
AID765520Selectivity factor, ratio of IC50 for human CYP11B2 to IC50 for human CYP11B12013Journal of medicinal chemistry, Aug-08, Volume: 56, Issue:15
Cushing's syndrome: development of highly potent and selective CYP11B1 inhibitors of the (pyridylmethyl)pyridine type.
AID1174179Inhibition of human placental microsomal CYP19 using [1beta-3H]androstenedione substrate pre-incubated for 5 mins by scintillation counting method2015European journal of medicinal chemistry, Jan-07, Volume: 89Discovery of new 7-substituted-4-imidazolylmethyl coumarins and 4'-substituted-2-imidazolyl acetophenones open analogues as potent and selective inhibitors of steroid-11β-hydroxylase.
AID549714Inhibition of human aldosterone synthase expressed in chinese hamster V79 cells using 11-deoxycorticosterone as substrate2011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2).
AID1162198Inhibition of human CYP11B2 expressed in hamster V79MZh cells using [1,2-3H]-11-deoxycorticosterone as substrate2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Potent 11β-hydroxylase inhibitors with inverse metabolic stability in human plasma and hepatic S9 fractions to promote wound healing.
AID1402025Inhibition of human 11beta-HSD1 expressed in HEK293 cell lysates at 50 uM using [1,2-3H]-cortisone as substrate preincubated for 10 mins followed by substrate addition in presence of NADPH by scintillation counting relative to control2018European journal of medicinal chemistry, Jan-01, Volume: 143Accelerated skin wound healing by selective 11β-Hydroxylase (CYP11B1) inhibitors.
AID1177642Inhibition of human aldosterone synthase expressed in V79 MZ cells pretreated with compound for 1 hr followed by addition of 500 nM 11-deoxycorticosterone for 1hr by HPLC analysis2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Aldosterone synthase inhibitors as promising treatments for mineralocorticoid dependent cardiovascular and renal diseases.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1134146Inhibition of bovine adrenal gland 11beta-hydroxylase assessed as amount of corticosterone production using 11 nmol [14C]-deoxycorticosterone measured per 5 mins at 2 nmol (Rvb = 1.3 +/- 0.04 nmol)1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
New inhibitors of steroid 11beta-hydroxylase. Structure--activity relationship studies of metyrapone-like compounds.
AID1162192Inhibition of human CYP17 expressed in Escherichia coli using progesterone as substrate at 2 uM2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Potent 11β-hydroxylase inhibitors with inverse metabolic stability in human plasma and hepatic S9 fractions to promote wound healing.
AID765518Inhibition of human CYP17 expressed in Escherichia coli co-expressing rat NADPH-P450 reductase using progesterone as substrate at 2 uM relative to control2013Journal of medicinal chemistry, Aug-08, Volume: 56, Issue:15
Cushing's syndrome: development of highly potent and selective CYP11B1 inhibitors of the (pyridylmethyl)pyridine type.
AID1162197Half life in human liver S9 fraction by LC-MS/MS analysis2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Potent 11β-hydroxylase inhibitors with inverse metabolic stability in human plasma and hepatic S9 fractions to promote wound healing.
AID549784Inhibition of human CYP17 expressed in Escherichia coli at 2000 nM using progesterone as substrate2011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2).
AID1134147Inhibition of bovine adrenal gland 11beta-hydroxylase assessed as amount of corticosterone production using 11 nmol [14C]-deoxycorticosterone measured per 5 mins at 2 nmol1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
New inhibitors of steroid 11beta-hydroxylase. Structure--activity relationship studies of metyrapone-like compounds.
AID549715Inhibition of human steroid-11beta-hydroxylase expressed in chinese hamster V79 cells using 11-deoxycorticosterone as substrate2011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2).
AID427879Displacement of [3H]ethynylpropylbicycloorthobenzoate from GABA receptor from rat cortical membrane at 100 uM by scintillation counting in absence of GABA2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Structure-activity relationship of etomidate derivatives at the GABA(A) receptor: Comparison with binding to 11beta-hydroxylase.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1134141Inhibition of bovine adrenal gland 11beta-hydroxylase assessed as inhibition of [14C]-deoxycorticosterone hydroxylation at 2 uM1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
New inhibitors of steroid 11beta-hydroxylase. Structure--activity relationship studies of metyrapone-like compounds.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID549716Selectivity ratio of IC50 for human steroid-11beta-hydroxylase to IC50 for human aldosterone synthase2011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2).
AID553068Inhibition of human recombinant CYP17 expressed in Escherichia coli at 2 uM using progesterone substrate2011ACS medicinal chemistry letters, Jan-13, Volume: 2, Issue:1
First Selective CYP11B1 Inhibitors for the Treatment of Cortisol-Dependent Diseases.
AID1203963Inhibition of human CYP19 expressed in hamster fibroblast using 500 nM [1beta-3H] androstenedione as substrate by HPLC analysis2015European journal of medicinal chemistry, , Volume: 96Identification of 4-(4-nitro-2-phenethoxyphenyl)pyridine as a promising new lead for discovering inhibitors of both human and rat 11β-Hydroxylase.
AID289115Inhibition of CYP450-mediated tangeretin demethylation in Aspergillus niger ATCC 9142 assessed as relative activity at 0.5 mM2007Journal of natural products, Jun, Volume: 70, Issue:6
Biotransformation of polymethoxylated flavonoids: access to their 4'-O-demethylated metabolites.
AID1402020Half life in human liver S9 fraction at 1 uM up to 60 mins in presence of NADPH/UDPGA by LC-MS/MS analysis2018European journal of medicinal chemistry, Jan-01, Volume: 143Accelerated skin wound healing by selective 11β-Hydroxylase (CYP11B1) inhibitors.
AID1449101Half life in rat liver S9 fractions at 1 uM in presence of NADPH/UDPGA by LC-MS/MS analysis2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Lead Optimization Generates CYP11B1 Inhibitors of Pyridylmethyl Isoxazole Type with Improved Pharmacological Profile for the Treatment of Cushing's Disease.
AID765517Inhibition of microsomal CYP19 in human placenta using [1beta-3H]-androstenedione as substrate at 2 uM by 3H2O method relative to control2013Journal of medicinal chemistry, Aug-08, Volume: 56, Issue:15
Cushing's syndrome: development of highly potent and selective CYP11B1 inhibitors of the (pyridylmethyl)pyridine type.
AID652428Inhibition of human CYP11B1 expressed in hamster V79 MZ cells using [3H] 11 deoxycorticosterone as substrate by HPLC radioflow detector2011ACS medicinal chemistry letters, Aug-11, Volume: 2, Issue:8
Optimization of the First Selective Steroid-11β-hydroxylase (CYP11B1) Inhibitors for the Treatment of Cortisol Dependent Diseases.
AID1174183Selectivity index, ratio of IC50 for human CYP11B2 to IC50 for human CYP11B12015European journal of medicinal chemistry, Jan-07, Volume: 89Discovery of new 7-substituted-4-imidazolylmethyl coumarins and 4'-substituted-2-imidazolyl acetophenones open analogues as potent and selective inhibitors of steroid-11β-hydroxylase.
AID3091Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase1984Journal of medicinal chemistry, Jan, Volume: 27, Issue:1
Structure-activity relationship study of the inhibition of adrenal cortical 11 beta-hydroxylase by new metyrapone analogues.
AID549713Inhibition of human steroid-11beta-hydroxylase expressed in chinese hamster V79 cells at 500 nM using 11-deoxycorticosterone as substrate2011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2).
AID1402021Inhibition of human CYP17A1 expressed in Escherichia coli XL1 at 2 uM using [3H]-progesterone as substrate preincubated with substrate for 5 mins measured after 45 mins by HPLC analysis2018European journal of medicinal chemistry, Jan-01, Volume: 143Accelerated skin wound healing by selective 11β-Hydroxylase (CYP11B1) inhibitors.
AID549786Inhibition of human placental CYP19 at 500 nM using androstenedione as substrate2011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2).
AID553065Inhibition of human CYP11B1 expressed in hamster V79MZ cells using 11-deoxycorticosterone substrate2011ACS medicinal chemistry letters, Jan-13, Volume: 2, Issue:1
First Selective CYP11B1 Inhibitors for the Treatment of Cortisol-Dependent Diseases.
AID1449095Inhibition of human CYP11B1 expressed in hamster V79MZ cells using [1,2-3H]-11-deoxycorticosterone as substrate after 6 hrs by HPLC analysis2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Lead Optimization Generates CYP11B1 Inhibitors of Pyridylmethyl Isoxazole Type with Improved Pharmacological Profile for the Treatment of Cushing's Disease.
AID1203962Inhibition of human CYP11B2 expressed in hamster fibroblast using 100 nM [3H]-11-deoxycorticosterone as substrate after 45 mins by HPLC analysis2015European journal of medicinal chemistry, , Volume: 96Identification of 4-(4-nitro-2-phenethoxyphenyl)pyridine as a promising new lead for discovering inhibitors of both human and rat 11β-Hydroxylase.
AID428564Inhibition of CYP3A42009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.
AID1134143Inhibition of bovine adrenal gland 11beta-hydroxylase assessed as inhibition of [14C]-deoxycorticosterone hydroxylation1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
New inhibitors of steroid 11beta-hydroxylase. Structure--activity relationship studies of metyrapone-like compounds.
AID1402027Inhibition of human 11beta-HSD2 expressed in HEK293 cell lysates at 200 uM using [1,2,6,7-3H]-cortisol as substrate preincubated for 10 mins followed by substrate addition in presence of NAD by scintillation counting relative to control2018European journal of medicinal chemistry, Jan-01, Volume: 143Accelerated skin wound healing by selective 11β-Hydroxylase (CYP11B1) inhibitors.
AID1449098Inhibition of rat CYP11B1 expressed in hamster V79MZ cells using [1,2-3H]-11-deoxycorticosterone as substrate after 6 hrs by HPLC analysis2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Lead Optimization Generates CYP11B1 Inhibitors of Pyridylmethyl Isoxazole Type with Improved Pharmacological Profile for the Treatment of Cushing's Disease.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1174184Selectivity index, ratio of IC50 for human placental microsomal CYP19 to IC50 for human CYP11B12015European journal of medicinal chemistry, Jan-07, Volume: 89Discovery of new 7-substituted-4-imidazolylmethyl coumarins and 4'-substituted-2-imidazolyl acetophenones open analogues as potent and selective inhibitors of steroid-11β-hydroxylase.
AID327555Displacement of [131I]IMTO from CYP450c 11 in Wistar rat adrenal membrane2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
New selective inhibitors of steroid 11beta-hydroxylation in the adrenal cortex. Synthesis and structure-activity relationship of potent etomidate analogues.
AID625278FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of no concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID1174182Inhibition of human CYP11B2 expressed in hamster V79MZh11B2 cells using [1,2-3H]-11-deoxycorticosterone substrate incubated for 25 mins by HPLC method2015European journal of medicinal chemistry, Jan-07, Volume: 89Discovery of new 7-substituted-4-imidazolylmethyl coumarins and 4'-substituted-2-imidazolyl acetophenones open analogues as potent and selective inhibitors of steroid-11β-hydroxylase.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID553066Inhibition of human CYP11B2 expressed in hamster V79MZ cells using 11-deoxycorticosterone substrate2011ACS medicinal chemistry letters, Jan-13, Volume: 2, Issue:1
First Selective CYP11B1 Inhibitors for the Treatment of Cortisol-Dependent Diseases.
AID1402022Inhibition of human 11beta-HSD1 expressed in HEK293 cell lysates at 200 uM using [1,2-3H]-cortisone as substrate preincubated for 10 mins followed by substrate addition in presence of NADPH by scintillation counting relative to control2018European journal of medicinal chemistry, Jan-01, Volume: 143Accelerated skin wound healing by selective 11β-Hydroxylase (CYP11B1) inhibitors.
AID1134144Inhibition of bovine adrenal gland 11beta-hydroxylase assessed as amount of corticosterone production using 22 nmol [14C]-deoxycorticosterone measured per 5 mins at 2 nmol (Rvb = 1.3 +/- 0.04 nmol)1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
New inhibitors of steroid 11beta-hydroxylase. Structure--activity relationship studies of metyrapone-like compounds.
AID765521Inhibition of human CYP11B2 expressed in hamster V79MZh cells using [1,2-3H]-11-deoxycorticosterone as substrate2013Journal of medicinal chemistry, Aug-08, Volume: 56, Issue:15
Cushing's syndrome: development of highly potent and selective CYP11B1 inhibitors of the (pyridylmethyl)pyridine type.
AID1203964Inhibition of rat CYP11B1 expressed in hamster fibroblast using 500 nM [3H]-11-deoxycorticosterone as substrate after 7 hrs by HPLC analysis2015European journal of medicinal chemistry, , Volume: 96Identification of 4-(4-nitro-2-phenethoxyphenyl)pyridine as a promising new lead for discovering inhibitors of both human and rat 11β-Hydroxylase.
AID1203965Selectivity index, ratio of IC50 for human CYP11B2 to IC50 for human CYP11B12015European journal of medicinal chemistry, , Volume: 96Identification of 4-(4-nitro-2-phenethoxyphenyl)pyridine as a promising new lead for discovering inhibitors of both human and rat 11β-Hydroxylase.
AID652431Selectivity ratio of IC50 for human CYP11B2 to IC50 for human CYP11B12011ACS medicinal chemistry letters, Aug-11, Volume: 2, Issue:8
Optimization of the First Selective Steroid-11β-hydroxylase (CYP11B1) Inhibitors for the Treatment of Cortisol Dependent Diseases.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1162191Inhibition of human CYP11B1 expressed in hamster V79MZh cells using [1,2-3H]-11-deoxycorticosterone as substrate2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Potent 11β-hydroxylase inhibitors with inverse metabolic stability in human plasma and hepatic S9 fractions to promote wound healing.
AID652429Inhibition of human CYP11B2 expressed in hamster V79 MZ cells using [3H] 11 deoxycorticosterone as substrate by HPLC radioflow detector2011ACS medicinal chemistry letters, Aug-11, Volume: 2, Issue:8
Optimization of the First Selective Steroid-11β-hydroxylase (CYP11B1) Inhibitors for the Treatment of Cortisol Dependent Diseases.
AID1449131Inhibition of CYP11B1 in Sprague-Dawley rat adrenal tissue using 11-deoxycorticosterone as substrate after 4 hrs by SPA2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Lead Optimization Generates CYP11B1 Inhibitors of Pyridylmethyl Isoxazole Type with Improved Pharmacological Profile for the Treatment of Cushing's Disease.
AID681586TP_TRANSPORTER: quantitative PCR in vivo, liver of mouse2003Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 31, Issue:11
Induction of ABCC3 (MRP3) by pregnane X receptor activators.
AID549712Inhibition of human aldosterone synthase expressed in chinese hamster V79 cells at 500 nM using 11-deoxycorticosterone as substrate2011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2).
AID1203961Inhibition of human CYP11B1 expressed in hamster fibroblast using 100 nM [3H]-11-deoxycorticosterone as substrate after 25 mins by HPLC analysis2015European journal of medicinal chemistry, , Volume: 96Identification of 4-(4-nitro-2-phenethoxyphenyl)pyridine as a promising new lead for discovering inhibitors of both human and rat 11β-Hydroxylase.
AID1174181Inhibition of human CYP11B1 expressed in hamster V79MZh11B1 cells using [1,2-3H]-11-deoxycorticosterone substrate incubated for 25 mins by HPLC method2015European journal of medicinal chemistry, Jan-07, Volume: 89Discovery of new 7-substituted-4-imidazolylmethyl coumarins and 4'-substituted-2-imidazolyl acetophenones open analogues as potent and selective inhibitors of steroid-11β-hydroxylase.
AID1174180Inhibition of human CYP17 expressed in Escherichia coli using [3H]-progesterone substrate pre-incubated for 5 mins at 2.5 uM in presence of rat P450 reductase by HPLC method2015European journal of medicinal chemistry, Jan-07, Volume: 89Discovery of new 7-substituted-4-imidazolylmethyl coumarins and 4'-substituted-2-imidazolyl acetophenones open analogues as potent and selective inhibitors of steroid-11β-hydroxylase.
AID1134145Inhibition of bovine adrenal gland 11beta-hydroxylase assessed as amount of corticosterone production using 22 nmol [14C]-deoxycorticosterone measured per 5 mins at 2 nmol1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
New inhibitors of steroid 11beta-hydroxylase. Structure--activity relationship studies of metyrapone-like compounds.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1449097Selectivity ratio of IC50 for human CYP11B2 expressed in hamster V79MZ cells to IC50 for human CYP11B1 expressed in hamster V79MZ cells2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Lead Optimization Generates CYP11B1 Inhibitors of Pyridylmethyl Isoxazole Type with Improved Pharmacological Profile for the Treatment of Cushing's Disease.
AID427878Displacement of [3H]ethynylpropylbicycloorthobenzoate from GABA receptor from rat cortical membrane at 100 uM by scintillation counting in presence of 1 uM GABA2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Structure-activity relationship of etomidate derivatives at the GABA(A) receptor: Comparison with binding to 11beta-hydroxylase.
AID1402019Inhibition of human placental microsomal CYP19A1 at 2 uM using [1beta-3H]androstenedione after 21 mins by liquid scintillation spectrometry2018European journal of medicinal chemistry, Jan-01, Volume: 143Accelerated skin wound healing by selective 11β-Hydroxylase (CYP11B1) inhibitors.
AID765522Inhibition of human CYP11B1 expressed in hamster V79MZh cells using [1,2-3H]-11-deoxycorticosterone as substrate2013Journal of medicinal chemistry, Aug-08, Volume: 56, Issue:15
Cushing's syndrome: development of highly potent and selective CYP11B1 inhibitors of the (pyridylmethyl)pyridine type.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID553069Inhibition of human placental microsomes CYP19 at 500 nM using androstenedione substrate2011ACS medicinal chemistry letters, Jan-13, Volume: 2, Issue:1
First Selective CYP11B1 Inhibitors for the Treatment of Cortisol-Dependent Diseases.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1162193Inhibition of human placental CYP19 using [1beta-3H]androstenedione as substrate at 2 uM by 3H2O-method2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Potent 11β-hydroxylase inhibitors with inverse metabolic stability in human plasma and hepatic S9 fractions to promote wound healing.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1177643Inhibition of human CYP11B1 expressed in V79 MZ cells pretreated with compound for 1 hr followed by addition of 500 nM 11-deoxycorticosterone for 3 hrs by HPLC analysis2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Aldosterone synthase inhibitors as promising treatments for mineralocorticoid dependent cardiovascular and renal diseases.
AID1402018Inhibition of human CYP11B1 expressed in hamster V79MZ cells using [1,2-3H]-11-deoxycorticosterone as substrate after 6 hrs by HPTLC analysis2018European journal of medicinal chemistry, Jan-01, Volume: 143Accelerated skin wound healing by selective 11β-Hydroxylase (CYP11B1) inhibitors.
AID553067Selectivity index, ratio of IC50 for human CYP11B2 to IC50 for human CYP11B12011ACS medicinal chemistry letters, Jan-13, Volume: 2, Issue:1
First Selective CYP11B1 Inhibitors for the Treatment of Cortisol-Dependent Diseases.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1345266Human CYP11B1 (CYP11, CYP17, CYP19, CYP20 and CYP21 families)2011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,194)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902182 (68.32)18.7374
1990's427 (13.37)18.2507
2000's295 (9.24)29.6817
2010's238 (7.45)24.3611
2020's52 (1.63)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 61.17

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index61.17 (24.57)
Research Supply Index8.17 (2.92)
Research Growth Index4.27 (4.65)
Search Engine Demand Index108.54 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (61.17)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials128 (3.75%)5.53%
Reviews147 (4.30%)6.00%
Case Studies192 (5.62%)4.05%
Observational0 (0.00%)0.25%
Other2,948 (86.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (18)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Acute Consequences Of Food-induced Glucocorticoid Secretion In Healthy Individuals - A Double-blind, Randomized, Placebo-controlled Cross-over Study [NCT05167084]Early Phase 120 participants (Actual)Interventional2022-02-08Completed
Antiglucocorticoid Augmentation of antiDepressants in Depression [NCT01375920]Phase 3190 participants (Actual)Interventional2011-02-28Completed
Effects of the Addition of Metyrapone to Antidepressant Therapy in Depression With Dexamethasone Suppression Test Non-suppression. [NCT03491696]Phase 414 participants (Anticipated)Interventional2018-12-22Recruiting
A Phase 1b, Randomized, Double-Blinded, Multiple-Dose, Placebo Controlled, Crossover Study To Evaluate The Safety, Tolerability And Pharmacokinetic Effects Of A Metyrapone And Oxazepam Combination (EMB-001) When Co-Administered With Cocaine [NCT02856854]Phase 118 participants (Actual)Interventional2016-07-31Completed
Metabolic, Pressor and Neuropsychological Effects of Metyrapone Treatment in Patients With Hypercortisolism [NCT05255900]20 participants (Anticipated)Observational2022-04-28Recruiting
A Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Two Dose Combinations of Metyrapone and Oxazepam in the Treatment of Cocaine Addiction [NCT00567814]45 participants (Anticipated)Interventional2007-12-31Completed
[NCT00006270]32 participants Observational1998-02-28Active, not recruiting
Cocaine-Metyrapone Interaction Study [NCT00033098]Phase 112 participants Interventional2001-11-30Active, not recruiting
Stress Biomarkers:Attaching Biological Meaning to Field Friendly Salivary Measures [NCT01673087]Phase 1256 participants (Actual)Interventional2012-10-31Completed
Placebo-Controlled, Randomized, Blinded, Double-Dummy, Crossover Study to Investigate the Attenuation of ACTH Activation Induced by Metyrapone With a Single Dose of GSK561679 or Alprazolam in Healthy Volunteers [NCT00426608]Phase 120 participants (Actual)Interventional2006-10-06Completed
Double-Blind, Placebo Controlled Trial of Metyrapone as Augmenting Agent in the Treatment of Major Depression [NCT00125554]Phase 263 participants Interventional1998-05-31Completed
Metyrapone Intervention in Patients With Mild Autonomous Cortisol Secretion (MACS) [NCT06106295]Phase 230 participants (Anticipated)Interventional2023-12-19Recruiting
The Effects of Cortisol Blockade on Nutritional Sympathetic Nervous System Responsiveness in Overweight and Obese Subjects With Metabolic Syndrome [NCT01620684]Phase 424 participants (Anticipated)Interventional2013-02-28Recruiting
Phase 1 Combined Single and Multiple Rising Dose Study of the Safety and Pharmacokinetics of Metyrapone/Oxazepam Combination (EMB-001) [NCT02406066]Phase 124 participants (Actual)Interventional2015-03-31Completed
The Role of Glucocorticoids to Maintain Energy Homeostasis During Starvation [NCT05919992]Early Phase 120 participants (Anticipated)Interventional2023-05-15Recruiting
Efficacy and Safety of Combination EMB-001 as a Potential Smoking Cessation Treatment [NCT04868253]Phase 2/Phase 325 participants (Anticipated)Interventional2021-05-19Recruiting
Diagnosis of Central Adrenal Insufficiency in Patients With Prader-Willi Syndrome [NCT02368379]23 participants (Actual)Interventional2014-03-31Completed
Prospective, Single Arm, Open-label, Multicenter, International Study to Assess the Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome During a 12-week Treatment Period Followed by an Extension Period of 24 Weeks [NCT02297945]Phase 350 participants (Actual)Interventional2015-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]